Antidepressant medications: a comprehensive review of efficacy, safety, and future directions

INTRODUCTION

Depression is a complex and debilitating psychiatric disorder that significantly affects emotional, cognitive, and physical functioning.¹ It is characterized by a persistent feeling of sadness, loss of interest or pleasure in daily activities, fatigue, impaired concentration, and disturbed sleep or appetite.¹ According to the World Health Organization (WHO), depression is one of the leading causes of disability worldwide, contributing substantially to the global disease burden.² Its impact extends beyond the individual, affecting families, workplaces, and societies at large.³ Despite increasing awareness and improved diagnostic practices, the prevalence of depression continues to rise, emphasizing the need for effective and accessible treatment strategies.³

Pharmacotherapy has long been considered the cornerstone of managing depressive and mood disorders.⁴ Antidepressant medications are designed to alleviate symptoms by modulating neurochemical imbalances, particularly within serotonergic, noradrenergic, and dopaminergic pathways.⁴ The monoamine hypothesis, which postulates that depression arises from deficiencies in neurotransmitters such as serotonin, norepinephrine, and dopamine, has historically guided drug development.⁵ Based on this framework, several classes of antidepressants have been developed, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs).⁶ These medications, though effective, differ significantly in their efficacy, tolerability, and side effect profiles.⁶

Despite advancements, the management of depression remains challenging.⁷ A considerable proportion of patients either exhibit partial response or fail to respond to conventional antidepressant therapy, leading to treatment-resistant depression (TRD).⁷ Moreover, adverse effects such as gastrointestinal disturbances, weight gain, sexual dysfunction, and emotional blunting often compromise adherence and overall treatment success.⁸ These limitations highlight the pressing need for more targeted, rapid-acting, and individualized therapeutic options.⁹

Recent years have witnessed substantial progress in the field of psychopharmacology, paving the way for novel antidepressant strategies that move beyond the traditional monoaminergic paradigm.¹⁰ Agents such as ketamine and its derivative esketamine have demonstrated rapid-onset antidepressant effects, offering hope for individuals with TRD.¹⁰ Similarly, multimodal antidepressants like vortioxetine not only improve mood but also enhance cognitive functioning by interacting with multiple neurotransmitter systems.¹¹ In parallel, the emergence of personalized medicine and pharmacogenomics has introduced the possibility of tailoring antidepressant therapy to an individual’s genetic profile, thereby optimizing treatment efficacy and minimizing side effects.¹²

Furthermore, the exploration of psychedelic-assisted therapies, including the controlled use of psilocybin and MDMA, represents a paradigm shift in depression treatment.¹³ These interventions, combined with psychotherapy, have shown promising outcomes in patients unresponsive to standard medications.¹⁴ The growing understanding of neuroplasticity, inflammatory mechanisms, and glutamatergic pathways has also expanded the scientific horizon, leading to the identification of new molecular targets for drug discovery.¹⁵

Given these developments, it is crucial to synthesize the expanding body of evidence on antidepressant pharmacotherapy.⁶ This review aims to provide a comprehensive analysis of current and emerging antidepressant medications, examining their mechanisms of action, therapeutic efficacy, safety profiles, and potential future directions.⁶ By integrating findings from recent clinical studies and meta-analyses, the review seeks to enhance understanding of antidepressant treatment paradigms and inform the evolution of precision psychiatry for improved mental health outcomes.

METHODS

This review employed a systematic and comprehensive approach to identify, evaluate, and synthesize current evidence on antidepressant medications, focusing on their mechanisms of action, efficacy, safety, emerging therapies, and future directions.¹⁶

A structured literature search was conducted across three major biomedical databases: PubMed, Scopus, and Web of Science, ensuring a broad coverage of peer-reviewed publications in the field of psychopharmacology.¹⁶

The search strategy incorporated a combination of controlled vocabulary terms, Medical Subject Headings (MeSH), and free-text keywords to maximize retrieval of relevant studies.¹⁷ Key search terms included: “antidepressant drugs,” “mechanism of action,” “efficacy,” “safety,” “treatment-resistant depression,” “rapid-acting antidepressants,” “personalized medicine,” “pharmacogenomics,” and “future perspectives.” Boolean operators (AND, OR) and truncation symbols were applied to refine results and capture variations in terminology.

Inclusion criteria

Inclusion criteria were defined to ensure high-quality and relevant evidence. Studies were included if they were peer-reviewed, published in English between 2000 and 2024, and focused on clinical, pharmacological, or mechanistic aspects of antidepressant therapy. Randomized controlled trials (RCTs) and observational studies, as well as meta-analyses and systematic reviews, were considered to provide a comprehensive perspective. Articles addressing novel therapeutic strategies, treatment-resistant depression, and emerging interventions were prioritized.

Exclusion criteria

Exclusion criteria encompassed studies that were non-peer-reviewed, published in languages other than English, or focused on non-pharmacological interventions exclusively. Studies with insufficient methodological quality or lacking primary data on efficacy, safety, or mechanisms were also excluded.

The study selection process followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines.¹⁷ Duplicates were removed, and titles and abstracts were screened for relevance. Full texts of potentially eligible articles were retrieved and independently reviewed by the authors. Discrepancies were resolved through discussion and consensus.

After rigorous screening, a total of 35 studies were included in the final review. Data were extracted and organized under thematic headings, including mechanisms of action, clinical efficacy, adverse effects, safety, emerging therapies, and future research directions. The synthesis of evidence was qualitative, emphasizing the integration of clinical, pharmacological, and mechanistic insights to provide a comprehensive understanding of current and emerging antidepressant pharmacotherapy.

STUDY SELECTION PROCESS

The study selection process was conducted systematically to ensure the inclusion of high-quality and relevant evidence, following the PRISMA guidelines.¹⁷

MECHANISMS OF ACTION OF ANTIDEPRESSANT MEDICATIONS

Antidepressant medications exert their therapeutic effects primarily through modulation of neurochemical pathways that are dysregulated in depression.¹⁸ The prevailing neurobiological framework—the monoamine hypothesis—posits that deficiencies or imbalances in neurotransmitters such as serotonin (5-HT), norepinephrine (NE), and dopamine (DA) contribute to depressive symptoms.¹⁸ Antidepressants aim to restore these neurochemical levels, thereby improving mood, cognitive function, and overall emotional regulation.¹⁹ Beyond traditional monoaminergic mechanisms, recent advancements have highlighted additional targets, including glutamatergic neurotransmission, neuroplasticity, and inflammatory pathways, reflecting a more nuanced understanding of depression’s pathophysiology.¹⁵

Selective serotonin reuptake inhibitors

SSRIs, such as fluoxetine, sertraline, and escitalopram, represent the first-line pharmacological treatment for major depressive disorder due to their efficacy and favorable safety profile.²⁰ These agents function by selectively inhibiting the serotonin transporter (SERT) on presynaptic neurons, preventing the reuptake of serotonin from the synaptic cleft.²¹ This inhibition increases extracellular serotonin levels, enhancing postsynaptic receptor stimulation and facilitating downstream signaling cascades involved in mood regulation.²¹

Chronic SSRI administration has been shown to induce neuroadaptive changes, including upregulation of neurotrophic factors such as brain-derived neurotrophic factor (BDNF), which promotes synaptic plasticity and neuronal resilience—key processes implicated in the sustained antidepressant effect.²²

Serotonin-norepinephrine reuptake inhibitors

SNRIs, including venlafaxine, duloxetine, and desvenlafaxine, inhibit the reuptake of both serotonin and norepinephrine by blocking SERT and norepinephrine transporters (NET).²³ The dual inhibition broadens the pharmacological profile of these drugs, enhancing mood regulation and improving symptoms of comorbid anxiety. By increasing synaptic concentrations of serotonin and norepinephrine, SNRIs potentiate neurotransmission in cortical and limbic pathways, which are essential for emotional processing, arousal, and cognitive function.²⁴ In addition, chronic SNRI use promotes downstream neuroplastic adaptations and may modulate hypothalamic-pituitary-adrenal (HPA) axis activity, further contributing to therapeutic effects.¹⁸

Tricyclic antidepressants

Tricyclic antidepressants (TCAs), including amitriptyline, nortriptyline, imipramine, inhibit the reuptake of both serotonin and norepinephrine, similar to SNRIs.²⁰ However, their pharmacological profile extends beyond monoamine transporters, as they also interact with a variety of receptors, including histaminergic (H1), muscarinic cholinergic, and alpha-adrenergic receptors. This broad receptor activity underlies both therapeutic and adverse effects. By enhancing serotonergic and noradrenergic transmission, TCAs improve mood, reduce anxiety, and modulate pain pathways, but their anticholinergic and cardiovascular effects limit clinical tolerability.²⁵ Chronic TCA treatment also promotes synaptic plasticity and increases BDNF expression, aligning with the neurotrophic hypothesis of antidepressant action.²²

Rapid-acting agents and novel mechanisms

Recent innovations in antidepressant therapy have shifted attention toward rapid-onset agents such as ketamine and esketamine, which primarily modulate glutamatergic neurotransmission.²⁶ These agents act as NMDA receptor antagonists, leading to a transient increase in glutamate release and subsequent activation of AMPA receptors.²⁷ This cascade enhances synaptic plasticity through increased BDNF expression and activation of the mTOR signaling pathway, resulting in rapid alleviation of depressive symptoms within hours, particularly in treatment-resistant populations.²⁸

Multimodal antidepressants

Agents like vortioxetine exhibit multimodal activity by combining serotonin transporter inhibition with modulation of multiple 5-HT receptor subtypes (agonism at 5-HT1A, partial agonism at 5-HT1B, and antagonism at 5-HT3, 5-HT1D, and 5-HT7 receptors).²⁹ This dual mechanism not only enhances serotonergic neurotransmission but also influences dopaminergic and noradrenergic pathways indirectly.²⁹ The resultant effect is an improvement in mood, anxiety, and cognitive function, with a more favorable adverse effect profile compared to traditional SSRIs and SNRIs.¹¹

Personalized mechanisms and pharmacogenomics

Individual variability in drug response is influenced by genetic polymorphisms affecting cytochrome P450 enzymes, serotonin transporters, and receptor subtypes.³⁰ Personalized medicine and pharmacogenomic-guided therapy aim to optimize antidepressant selection and dosing by predicting efficacy and minimizing adverse effects.¹² This approach facilitates precision psychiatry, ensuring that mechanistic interventions are tailored to the patient’s unique neurochemical and genetic profile.³¹

Future directions

Emerging research is exploring non-monoaminergic targets such as neuroinflammatory pathways, neurotrophic signaling, and epigenetic modifications.³² Psychedelic-assisted therapies using compounds like psilocybin and MDMA appear to enhance neuroplasticity, promote affective processing, and restructure dysfunctional neural circuits, offering complementary mechanisms for treatment-resistant depression.¹³ Antidepressant medications act through complex and overlapping mechanisms, ranging from classical monoaminergic modulation to glutamatergic, neurotrophic, and multimodal effects.³³ Advances in rapid-acting agents, multimodal drugs, and personalized pharmacogenomics underscore a mechanistic evolution toward precision psychiatry, aiming to maximize therapeutic efficacy while minimizing adverse effects.³³

EFFICACY AND ADVERSE EFFECTS

The clinical efficacy of antidepressant medications has been extensively investigated over the past several decades through randomized controlled trials and meta-analyses.⁶ Antidepressants are considered effective in reducing the severity of depressive symptoms, particularly in patients with moderate to severe major depressive disorder (MDD).⁶ However, their therapeutic response can vary significantly based on drug class, individual biological factors, comorbidities, and treatment adherence.³⁴

Meta-analytic data have consistently demonstrated that antidepressants outperform placebo in improving depressive symptoms, although the magnitude of benefit is more pronounced in patients with severe depression.³⁵ In contrast, the effectiveness in mild cases of depression remains debated, with some studies suggesting only marginal differences from placebo responses.³⁶ Among different drug classes, SSRIs such as sertraline and escitalopram are widely regarded as first-line agents due to their favorable balance between efficacy and tolerability.²⁰ Similarly, SNRIs like venlafaxine and duloxetine offer robust efficacy, particularly for patients exhibiting both depressive and anxiety symptoms.²⁴

Comparative analyses indicate that newer antidepressants may provide advantages in onset of action and remission rates.³⁷ For instance, vortioxetine, a multimodal antidepressant, has demonstrated superior effects on cognitive function and overall symptom relief compared to conventional SSRIs.¹¹ Rapid-acting agents such as ketamine and esketamine have further revolutionized the treatment landscape by producing significant mood improvements within hours, offering hope for patients with treatment-resistant depression.¹⁰ These findings underscore the evolving nature of antidepressant efficacy, with emerging therapies targeting novel neurobiological pathways beyond monoamine regulation.³⁸

Despite proven efficacy, antidepressant medications are often associated with a range of adverse effects that can impact treatment adherence and quality of life.⁸ The side-effect profiles vary across drug classes and are primarily related to their pharmacological mechanisms. SSRIs commonly cause gastrointestinal disturbances (nausea, diarrhea), sexual dysfunction, insomnia, and headache.⁸ They may also induce weight changes and, in younger individuals, an increased risk of suicidal ideation during the early phase of treatment.³⁹ SNRIs, while effective, can lead to hypertension, dry mouth, sweating, and agitation due to noradrenergic stimulation.²³ TCAs are effective but often limited by their anticholinergic and cardiovascular adverse effects such as sedation, constipation, orthostatic hypotension, and cardiac arrhythmias.²⁰

The tolerability and safety of antidepressants remain critical determinants of treatment success.⁴⁰ While most adverse effects are mild and transient, some may necessitate discontinuation or switching of medications.⁴⁰ Long-term use also raises concerns about metabolic disturbances, emotional blunting, and withdrawal symptoms upon cessation.⁸ Therefore, clinical management should involve regular monitoring, patient education, and individualized dosing strategies to balance efficacy with safety.⁴⁰

Overall, while antidepressants continue to be the mainstay of depression management, optimizing therapeutic response requires careful selection of agents based on symptom profile, comorbid conditions, and patient preferences.⁶ The integration of pharmacogenomic testing and personalized medicine holds promise for predicting both efficacy and side-effect susceptibility, thereby improving clinical outcomes and enhancing patient compliance.¹²

SAFETY PROFILE

The safety profile of antidepressant medications is a critical consideration in clinical practice, as it directly influences patient adherence, long-term outcomes, and overall quality of life.⁴¹ While antidepressants are generally well-tolerated, their adverse effect patterns differ significantly across drug classes due to variations in pharmacodynamics and receptor specificity.⁴¹ Understanding these differences is essential for individualized therapy and risk minimization.

SSRIs are often considered the safest first-line agents due to their relative tolerability.⁸ Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and dyspepsia, as well as insomnia, headache, and mild anxiety during the initial phase of treatment.⁸ Sexual dysfunction—including decreased libido, anorgasmia, and erectile difficulties—is also frequently reported and can significantly impact treatment adherence.⁴² In rare cases, SSRIs may precipitate serotonin syndrome, particularly when combined with other serotonergic agents. Importantly, adolescents and young adults initiating SSRI therapy require careful monitoring due to an increased risk of suicidal ideation during early treatment.³⁹

SNRIs, while effective in both depressive and comorbid anxiety symptoms, can produce noradrenergic-related side effects such as elevated blood pressure, sweating, agitation, and palpitations.²³ TCAs are effective but are limited by their broader receptor activity, which may lead to sedation, anticholinergic effects (dry mouth, constipation, and urinary retention), orthostatic hypotension, and cardiotoxicity in overdose situations.²⁰ These safety concerns necessitate cautious use, particularly in elderly patients or those with cardiovascular comorbidities.⁴³ Emerging therapies such as ketamine and esketamine exhibit rapid-onset antidepressant effects, yet their safety profile requires vigilant monitoring due to transient dissociative symptoms, blood pressure elevation, and potential for misuse.⁴⁴ Multimodal agents like vortioxetine demonstrate a favorable tolerability profile, with lower incidences of sexual dysfunction and weight gain, making them suitable for long-term use.⁴⁵

Overall, the safety of antidepressants depends not only on the pharmacological class but also on individual patient factors including age, comorbidities, polypharmacy, and genetic predispositions.³⁰ Integrating personalized medicine approaches—including pharmacogenomic testing—into clinical practice offers the potential to predict adverse reactions, optimize dosing, and enhance overall treatment safety.¹² Clinicians must balance efficacy with tolerability by monitoring for side effects, adjusting regimens appropriately, and providing patient education to improve adherence and therapeutic outcomes.⁴⁶

RECENT ADVANCEMENTS AND EMERGING THERAPIES

Advances in antidepressant pharmacotherapy have expanded the treatment landscape beyond traditional monoaminergic agents, addressing unmet needs such as rapid symptom relief and treatment-resistant depression (TRD). Recent research focuses on developing therapies that act on novel neurobiological pathways, improve cognitive outcomes, and enable personalized treatment strategies.⁴⁷

RAPID-ONSET ANTIDEPRESSANTS

Conventional antidepressants typically require several weeks to achieve significant symptom relief, which poses challenges in severe or high-risk depression.⁶ In contrast, ketamine and its enantiomer esketamine have demonstrated rapid antidepressant effects, often within hours of administration.¹⁰ These agents primarily modulate the glutamatergic system, enhancing synaptic plasticity and downstream neurotrophic signaling, thereby offering a promising therapeutic option for patients unresponsive to first-line treatments.²⁷ Intranasal esketamine has gained regulatory approval for TRD, highlighting its clinical relevance and safety under monitored conditions.⁴⁸

MULTIMODAL ANTIDEPRESSANTS

Novel agents such as vortioxetine exemplify the multimodal approach by modulating multiple neurotransmitter systems, including serotonin receptor subtypes and serotonin transporters.²⁹ This pharmacological profile not only alleviates depressive symptoms but also improves cognitive function, addressing an often-overlooked dimension of depression.¹¹ Multimodal antidepressants offer a favorable balance of efficacy and tolerability, reducing common adverse effects like sexual dysfunction and weight gain.⁴⁵

PERSONALIZED MEDICINE AND PHARMACOGENOMICS

Advances in genomics and biomarker research have enabled individualized treatment strategies aimed at optimizing therapeutic response and minimizing adverse effects.⁴⁹ Genetic variations in cytochrome P450 enzymes, serotonin transporters, and receptor polymorphisms can influence drug metabolism, efficacy, and tolerability.³⁰ Incorporating pharmacogenomic testing into clinical practice has the potential to guide drug selection, predict side-effect susceptibility, and improve adherence, marking a significant step toward precision psychiatry.³¹

PSYCHEDELIC-ASSISTED THERAPY

Emerging evidence supports the use of controlled psychedelic compounds such as psilocybin and MDMA in combination with psychotherapy for patients with TRD.¹³ These interventions appear to promote rapid mood improvement and enhanced emotional processing by modulating neural circuits involved in affect regulation and neuroplasticity.¹⁴ Although still under investigation, psychedelic-assisted therapy represents a novel and promising paradigm in antidepressant treatment.⁵⁰

Collectively, these advancements underscore a shift toward innovative, mechanism-based, and individualized approaches in antidepressant therapy.⁴⁷ The integration of rapid-acting agents, multimodal drugs, pharmacogenomics, and novel therapeutic modalities holds significant promise for enhancing treatment outcomes, reducing the burden of treatment-resistant depression, and advancing the future of psychopharmacology.⁵¹

CHALLENGES AND FUTURE DIRECTIONS

Despite significant advancements in antidepressant pharmacotherapy, several clinical and scientific challenges persist.⁵² Treatment resistance remains a major hurdle, with an estimated 30–40% of patients failing to achieve remission with first-line therapies.⁷ This underscores the need for alternative strategies, including pharmacological augmentation, combination therapy, and the development of novel agents targeting non-monoaminergic pathways.⁵²

Precision psychiatry represents a promising avenue for addressing these challenges.⁴⁹ By integrating genomic data, biomarkers, and patient-specific characteristics, clinicians may tailor treatment strategies to individual profiles, improving efficacy and reducing adverse effects.⁴⁹ Personalized approaches have the potential to optimize drug selection, dosing, and monitoring, ultimately enhancing clinical outcomes.³¹

Emerging research also highlights the importance of exploring new molecular targets beyond traditional monoamine systems.⁵³ Glutamatergic modulation, neuroplasticity enhancement, and inflammatory pathways offer innovative therapeutic opportunities.³² Rapid-acting agents such as ketamine and esketamine exemplify this shift, demonstrating the benefits of targeting alternative neural mechanisms.²⁶ Additionally, psychedelic-assisted therapy represents a novel intervention for patients with treatment-resistant depression, providing insights into alternative neural pathways and psychotherapeutic synergy.⁵⁰

Other challenges include the long-term safety of newer agents, limited understanding of optimal dosing strategies, and accessibility of advanced therapies in diverse populations.⁵¹ Addressing these gaps requires ongoing research, large-scale clinical trials, and the development of guidelines that incorporate both efficacy and individualized safety considerations.^54,55

CONCLUSION

Antidepressant medications continue to serve as the cornerstone of pharmacological management for depressive disorders, providing substantial symptom relief for a majority of patients. However, challenges such as treatment resistance, adverse effects, and variable individual response underscore the need for more precise, effective, and patient-centered approaches. Recent advancements, including rapid-acting agents, multimodal antidepressants, personalized medicine, and psychedelic-assisted therapies, have expanded therapeutic possibilities and hold promise for improving outcomes in treatment-resistant and complex cases.

The integration of pharmacogenomic insights, novel molecular targets, and individualized treatment strategies is shaping the future of precision psychiatry, offering opportunities to enhance both efficacy and safety. Continued research into innovative pharmacological mechanisms, long-term tolerability, and patient-specific factors is essential to refine antidepressant therapy and optimize mental health outcomes. Ultimately, a combination of traditional and emerging strategies promises a more comprehensive, tailored, and effective approach to the management of depression, addressing both symptomatic relief and overall functional recovery.

ACKNOWLEDGEMENTS

The authors would like to thank the academic and institutional libraries for providing access to relevant scientific databases and research materials essential for this review. The authors also acknowledge the guidance, encouragement, and constructive feedback received from colleagues and mentors throughout the preparation of this manuscript.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. 1. World Health Organization. Depression and other common mental disorders: global health estimates. 2017. Available at: https://www.who.int/publications/i/item/depression-global-health-estimates. Accessed on 25 August 2025.
2. 2. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatr. 2022;9(2):137-50.
3. 3. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annual Rev Public Health. 2013;34:119-38.
4. 4. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends in Pharmacol Sci. 2004;25(7):351-7.
5. 5. Aan Het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. Can Med Assoc J. 2009;180(3):305-13.
6. 6. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):1357-66.
7. 7. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.
8. 8. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Primary Care Companion. J Clin Psychiatry. 2001;3(1):22-7.
9. 9. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 2007;22(6):323-9.
10. 10. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-42.
11. 11. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557-67.
12. 12. Tan G, Ward J, Luedtke A. Pharmacogenomics in depression: a systematic review of clinical studies. Pharmacogenom J. 2020;20(2):141-53.
13. 13. Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-27.
14. 14. Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):13187.
15. 15. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Med. 2016;22(3):238-49.
16. 16. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
17. 17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
18. 18. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. Can Med Assoc J. 2009;180(3):305-13.
19. 19. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20(24):9104-10.
20. 20. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58(1):19-36.
21. 21. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215-35.
22. 22. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54(7):597-606.
23. 23. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016;61(9):540-60.
24. 24. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-51.
25. 25. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8(2):67-104.
26. 26. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72(7):537-47.
27. 27. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013;73(12):1133-41.
28. 28. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-64.
29. 29. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589-600.
30. 30. Fabbri C, Serretti A. Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatr Rep. 2015;17(7):50.
31. 31. Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019;20(1):37-47.
32. 32. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-41.
33. 33. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-27.
34. 34. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66(8):974-81.
35. 35. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34-40.
36. 36. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
37. 37. Mulrow CD, Williams JW Jr, Chiquette E, Aguilar C, Hitchcock-Noel P, Lee S, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med. 2000;108(1):54-64.
38. 38. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.
39. 39. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-9.
40. 40. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155(11):772-85.
41. 41. Trivedi MH, Rush AJ, Carmody TJ, Donahue RM, Bolden-Watson C, Houser TL, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry. 2001;62(10):776-81.
42. 42. Clayton AH, McGarvey EL, Clavet GJ. The changes in sexual functioning questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33(4):731-45.
43. 43. Glassman AH, Bigger JT Jr. Antidepressant drugs and cardiovascular risk: a review of the evidence. J Clin Psychiatry. 2001;62:28-33.
44. 44. Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry. 2018;175(7):620-30.
45. 45. Baldwin DS, Chrones L, Florea I, Nielsen RZ, Nomikos GG, Palo W, et al. The safety and tolerability of vortioxetine. J Psychopharmacol. 2016;30(3):242-52.
46. 46. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. Combining medications to enhance depression outcomes (CO-MED). Am J Psychiatry. 2011;168(7):689-701.
47. 47. McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression. Am J Psychiatry. 2021;178(5):383-99.
48. 48. Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray. Am J Psychiatry. 2019;176(6):428-38.
49. 49. Zeier Z, Carpenter LL, Kalin NH, Rodriguez CI, McDonald WM, Widge AS, et al. Clinical implementation of pharmacogenomics for treatment-resistant depression. Mol Psychiatry. 2018;23(5):1181-93.
50. 50. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481-9.
51. 51. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399-405.
52. 52. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179-200.
53. 53. Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017;135(5):373-87.
54. 54. Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E, Häggström L, et al. Meta-analysis of randomized, placebo-controlled trials of vortioxetine for major depressive disorder. Ann Gen Psychiatry. 2016;15:33.
55. 55. Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, et al. Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry. 2021;54(1):5-17.